Physician profile
Heidi J Hunter
NPI 1992917785
$150,276.88
in general payments reported to CMS, 2019-2025
53 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 92% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $22K · 2021: $20K · 2022: $36K · 2023: $15K · 2024: $2,238 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,910 · Travel and Lodging: $1,530 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,368.25 |
| Food and Beverage | $5,909.92 |
| Travel and Lodging | $1,530.31 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $75,322.17 | 2019-2022 | |
| Abbvie INC. | $32,206.27 | 2019-2025 | |
| Allergan, INC. | $21,267.52 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $10,961.86 | 2023-2024 | Nuedexta |
| Boston Scientific Corporation | $2,028.54 | 2019 | |
| Jazz Pharmaceuticals INC. | $917.38 | 2022-2025 | Epidiolex |
| Supernus Pharmaceuticals, INC. | $837.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $757.40 | 2019-2025 | Austedo Xr, Uzedy, Ajovy |
| Emd Serono, INC. | $570.06 | 2019-2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $441.66 | 2019-2020 | |
| Pfizer INC. | $424.20 | 2019-2025 | |
| Amgen INC. | $378.25 | 2019-2022 | |
| Ucb, INC. | $370.20 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $369.68 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $312.65 | 2019-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.